Search Within

Alison Michele Schram

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (25)
  2. Meeting Abstract (19)
  3. Research Letter (1)
Groups
  1. Department of Medicine (45)
  2. Department of Pathology and Laboratory Medicine (45)
  3. Early Drug Development Service (45)
  4. Gynecologic Medicine Service (45)
  5. Solid Tumor Oncology Division (45)
  6. GSK Faculty (38)

More Groups

People
  1. Alexander Drilon (27)
  2. David Hyman (26)
  3. Michael Berger (23)
  4. Marc Ladanyi (16)
  5. Ahmet Zehir (13)
  6. Helen Won (12)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (2)
  4. 2022 (5)
  5. 2021 (7)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Cancer Research (8)
  3. Cancer Discovery (4)
  4. JCO Precision Oncology (4)
  5. Annals of Oncology (3)
  6. Nature Medicine (3)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. American Society of Clinical Oncology (14)
  3. Nature Publishing Group (7)
  4. Oxford University Press (3)
  5. Elsevier Inc. (2)
  6. American Society of Hematology (1)

More Publishers

Results (45)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors
    Journal Article

    Rao, M.; Merrill, M.; Troxel, M.; Chiang, S.; Momeni-Boroujeni, A.; Hensley, M. L.; Schram, A. M.
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
    Journal Article

    Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis
    Meeting Abstract

    Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
    Meeting Abstract

    Choudhury, N. J.; Harada, G.; Whiting, K.; Shen, R.; Yang, S. R.; Solit, D. B.; Berger, M. F.; Dinapoli, S.; Abou-Alfa, G. K.; Iyer, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
    Journal Article

    Murciano-Goroff, Y. R.; Schram, A. M.; Rosen, E. Y.; Won, H.; Gong, Y.; Noronha, A. M.; Janjigian, Y. Y.; Stadler, Z. K.; Chang, J. C.; Yang, S. R.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
    Journal Article

    Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save